Hindawi BioMed Research International Volume 2023, Article ID 9757348, 3 pages https://doi.org/10.1155/2023/9757348 Corrigendum Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” Brian Godman,1,2,3 Magdalene Wladysiuk,4,5 Stuart McTaggart,6 Amanj Kurdi,1,2,7 Eleonora Allocati,8 Mihajlo Jakovljevic ,9,10,11 Francis Kalemeera,12 Iris Hoxha,13 Anna Nachtnebel,14 Robert Sauermann,14 Manfred Hinteregger,14 Vanda Marković-Peković ,15 Biljana Tubic,16,17 Guenka Petrova ,18 Konstantin Tachkov,18 Juraj Slabý,19 Radka Nejezchlebova,19 Iva Selke Krulichová,20 Ott Laius,21 Gisbert Selke,22 Irene Langner,22 András Harsanyi,23 András Inotai ,24 Arianit Jakupi ,25 Svens Henkuzens,26 Kristina Garuolienė ,27 Jolanta Gulbinovič ,27 Patricia Vella Bonanno,1,28 Jakub Rutkowski,5 Skule Ingeberg,29 Øyvind Melien,29 Ileana Mardare,30 Jurij Fürst,31 Sean MacBride-Stewart,32 Carol Holmes,33 Caridad Pontes,34,35 Corinne Zara,34 Marta Turu Pedrola,34 Mikael Hoffmann,36 Vasileios Kourafalos,37 Alice Pisana ,38 Rita Banzi ,8 Stephen Campbell ,39,40 and Bjorn Wettermark41 1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK 2 Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa 3 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia 4 Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland 5 HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland 6 Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK 7 Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq 8 Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy 9 Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia 10 Institute of Comparative Economic Studies, Hosei University Tokyo, Japan 11 Department of Global Health Economics and Policy, University of Kragujevac, Serbia 12 Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia 13 Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania 14 Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria 15 Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina 16 Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina 17 Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina 18 Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria 19 State Institute for Drug Control, Prague, Czech Republic 20 Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic 21 State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia 22 Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany 23 Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary 24 Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary 25 Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo 26 Independent Consultant, Riga, Latvia 2 BioMed Research International 27 Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania 28 Department of Health Services Management, University of Malta, Valletta, Malta 29 Medicines Committee, Oslo University Hospitals, Oslo, Norway 30 Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania 31 Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia 32 Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK 33 NHS Lothian, Edinburgh, UK 34 Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain 35 Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain 36 NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden 37 National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece 38 Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden 39 Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK 40 NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK 41 Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden Correspondence should be addressed to Brian Godman; brian.godman@strath.ac.uk Received 8 August 2022; Accepted 8 August 2022; Published 7 April 2023 Copyright © 2023 Brian Godman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incor- rect. The corrected captions for Figures 3 and 4 appear below. BioMed Research International 3 70 % Insulin glargine 300 IU/ml 60 50 40 30 20 10 0 2015 2016 2017 2018 2019 2020 Year Albania Latvia Czech republic Norway Italy Slovenia Malta Bosnia and Herzegovina Scotland Hungary Sweden Lithuania Austria Poland Estonia Spain (Catalonia) Figure 3: Utilisation of insulin glargine 300 IU/ml (Gla-300) as a % of total insulin glargine (DDD based) across Europe over time. 80 % Insulin glargine biosimilar 70 60 50 40 30 20 10 0 2015 2016 2017 2018 2019 2020 Year Bosnia and herzegovina Czech Republic Hungary Lithuania Norway Scotland Slovenia Estonia Catalonia Poland Italy Sweden Bulgaria Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe. References [1] B. Godman, M. Wladysiuk, S. McTaggart et al., “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications,” BioMed Research International, vol. 2021, Article ID 9996193, 16 pages, 2021.